Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule.
dc.contributor.author | Schurink-van 't Klooster, Tessa M | |
dc.contributor.author | Donken, Robine | |
dc.contributor.author | Schepp, Rutger M | |
dc.contributor.author | van der Klis, Fiona R M | |
dc.contributor.author | de Melker, Hester E | |
dc.date.accessioned | 2019-02-12T11:15:04Z | |
dc.date.available | 2019-02-12T11:15:04Z | |
dc.date.issued | 2018-11-26 | |
dc.identifier.issn | 1873-2518 | |
dc.identifier.pmid | 30377068 | |
dc.identifier.doi | 10.1016/j.vaccine.2018.10.018 | |
dc.identifier.uri | http://hdl.handle.net/10029/622717 | |
dc.description.abstract | In this cohort study, we examined antibody levels and avidity after a two-dose schedule (0, 6 months) of the bivalent HPV-vaccine in girls routinely vaccinated in the Dutch HPV-vaccination program, up to 2 years following vaccination. A blood sample at 7, 12 and 24 months after the first dose and questionnaire data were collected (n = 56). HPV type-specific antibody concentrations (lU/ml) against seven types (HPV16/18/31/33/45/52/58) were assessed using a validated virus-like particles (VLP) multiplex immunoassay. Avidity was tested using a modification of this assay. Seropositivity for vaccine types HPV 16 and 18 was 100% up to month 24, but declined for HPV-types 31/33/45/52/58, although not statistically significant for HPV45. All Geometric Mean Concentrations (GMCs) declined by months 12 and 24, but remained high for HPV16/18. Between month 7 and 12, GMCs declined more for other types. High avidity antibodies were induced up to 24 months for vaccine types (75%, 76-78% and 81-82% at months 7, 12 and 24, respectively), but for other types antibody avidity was 16-29% at month 7, 20-32% at month 12 and 19-32% at month 24. GMCs declined over time for HPV-types 16/18/31/33/45/52/58, but remained high for vaccine-types HPV16/18 up to 24 months of follow-up. Antibody avidity was >75% for vaccine types but <35% for other HPV-types. Further follow-up of this cohort will provide insight into antibody and avidity kinetics over time. | en_US |
dc.language.iso | en | en_US |
dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
dc.subject | Antibody concentration | en_US |
dc.subject | Avidity | en_US |
dc.subject | GMC | en_US |
dc.subject | HPV | en_US |
dc.subject | Two-dose schedule | en_US |
dc.subject | Vaccine | en_US |
dc.title | Persistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule. | en_US |
dc.type | Article | en_US |
dc.identifier.journal | Vaccine 2018; 36(49):7580-7 | en_US |
dc.source.journaltitle | Vaccine | |
refterms.dateFOA | 2019-02-12T11:15:04Z |